Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 1, 2011, Pages 17-24

  Friedrich, C ^a   Ring, A ^a   Brand, T ^a   Sennewald, R ^a   Graefe Mody, E U ^a   Woerle, H J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Digoxin; DPP 4 inhibitor; Drug interaction; Linagliptin; Pharmacokinetics; Type 2 diabetes

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; LINAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DIGOXIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; YOUNG ADULT;

EID: 79954427139     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0028-y     Document Type: Article

References (32)

1. Aspen Europe GmbH (2010) Lanoxin 125 Tablets, Summary of Product Characteristics (last updated 8 March 2010). http://www.medicines.org.uk/EMC/ medicine/2174/SPC/Lanoxin+125+Tablets/. Accessed 17 Nov 2010
2. PV Balimane S Chong 2005 A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay Int J Pharmacol 301 80 88 10.1016/j.ijpharm.2005.05.034 1:CAS:528:DC%2BD2MXptVWhtLo%3D (Pubitemid 41206593)
3. Barnett AH, Harper R, Toorawa R, Patel S, Woerle H-J (2010) Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. Diabetologia 53(Suppl 1):S327 (Poster 823, presented at the European Association for the Study of Diabetes 46th Annual Meeting, Stockholm, Sweden. 20-24 September 2010)
4. S Blech E Ludwig-Schwellinger EU Gräfe-Mody B Withopf K Wagner 2010 The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab Dispos 38 667 678 20086031 10.1124/dmd.109.031476 1:CAS:528:DC%2BC3cXhtVOgsrnF
5. CF Deacon JJ Holst 2010 Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin Investig Drugs 19 133 140 19947894 10.1517/ 13543780903463862 1:CAS:528:DC%2BD1MXhsFCiurfL
6. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle H-J, Dugi KA (2011) Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab 13:258-267
7. M Eckhardt E Langkopf M Mark M Tadayyon L Thomas H Nar W Pfrengle B Guth R Lotz P Sieger H Fuchs F Himmelsbach 2007 8-(3-(R)-aminopiperidin-1-yl)-7-but- 2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J Med Chem 50 6450 6453 18052023 10.1021/jm701280z 1:CAS:528:DC%2BD2sXhtlyqs7vJ (Pubitemid 350309082)
8. FDA Draft Guidance on Drug Interactions (2006) US FDA Center for Biologics Evaluation and Research (CBER), September 2006. http://www.fda.gov/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093606.htm. Accessed 17 Nov 2010
9. T Forst B Uhlig-Laske A Ring U Graefe-Mody C Friedrich K Herbach H-J Woerle KA Dugi 2010 Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes Diabet Med 12 1409 1419 10.1111/j.1464-5491.2010.03131.x
10. MF Fromm 2000 P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs Int J Clin Pharmacol Ther 38 69 74 10706193 1:CAS:528:DC%2BD38XovVyksQ%3D%3D (Pubitemid 30077981)
11. Gomis R, Espadero R-M, Jones R, Woerle H-J, Dugi KA (2010) Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes. Poster 551-P, presented at the 70th scientific sessions of the American diabetes association, Orlando, Florida, June 25-29, 2010. Abstract available at: http://professional.diabetes. org/Abstracts-Display.aspx?TYP=1&CID=79499. Accessed 17 Nov 2010
12. EU Graefe-Mody S Padula A Ring B Withopf KA Dugi 2009 Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects Curr Med Res Opin 25 1963 1972 19552619 10.1185/03007990903094361 1:CAS:528:DC%2BD1MXoslalsro%3D
13. U Graefe-Mody S Huettner H Stähle A Ring KA Dugi 2010 Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin Int J Clin Pharmacol Ther 48 367 374 20497745 1:CAS:528:DC%2BC3cXhtVSlurzL
14. Graefe-Mody U, Friedrich C, Port A, Ring A, Heise T, Halabi A, Woerle H-J (2010b) Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in type 2 diabetes patients with renal impairment. Diabetologia, 53(Suppl 1): S326. Poster 822, presented at the European association for the study of diabetes 46th annual meeting, Stockholm, Sweden, 20-24 Sept 2010.
15. SM Haffner S Lehto T Rönnemaa K Pyörälä M Laakso 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229 234 9673301 10.1056/NEJM199807233390404 1:STN:280:DyaK1czivVKgsg%3D%3D (Pubitemid 28350165)
16. Hayward R (1987) Digitalis: the present position. In: Hamer J (ed) Drugs for heart disease, 2nd edn. Chapman and Hall, London, pp 145-193
17. YL He R Sabo G Sunkara MN Bizot GJ Rivierie S Leon M Ligueros-Saylan WP Dole D Howard 2007 Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers J Clin Pharmacol 47 998 1004 17660482 10.1177/0091270007301802 1:CAS:528:DC%2BD2sXps1Sjurs%3D (Pubitemid 47094094)
18. T Heise EU Graefe-Mody S Hüttner A Ring D Trommeshauser KA Dugi 2009 Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 11 786 794 19476474 10.1111/j.1463-1326.2009.01046.x 1:CAS:528:DC%2BD1MXpvV2jsLs%3D
19. Horn JR, Hansten PD (2004) Drug interactions with digoxin: the role of P-glycoprotein. Pharmacy Times. http://www.hanstenandhorn.com/hh-article10-04. pdf. Accessed 17 Nov 2010
20. S Hüttner EU Graefe-Mody B Withopf A Ring KA Dugi 2008 Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers J Clin Pharmacol 48 1171 1178 18812608 10.1177/0091270008323753
21. Karim A, Fleck P, Harris S, Weiss M, Zhang W, Mekki Q (2008) Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Clin Pharmacol Ther 83:S12-13 (Presented at the American society for clinical pharmacology and therapeutics, Orlando, Florida, April 2-5, 2008)
22. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Yoshiharu H, Sarashina A, Woerle H-J, Dugi KA (2010a) Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Poster 696-P, presented at the 70th scientific sessions of the American diabetes association, Orlando, Florida, June 25-29, 2010. Abstract available at: http://professional. diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79641. Accessed 17 Nov 2010
23. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Woerle H-J, Dugi KA (2010b) Linagliptin provides superior glycemic control compared to voglibose as monotherapy in Japanese patients with type 2 diabetes. Poster 632-P, presented at the 70th scientific sessions of the American diabetes association, Orlando, Florida, June 25-29, 2010. Abstract available at: http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79579. Accessed 17 Nov 2010
24. RB Kim 2003 Organic anion-transporting polypeptide (OATP) transporter family and drug disposition Eur J Clin Invest 33 Suppl 2 1 5 14641549 10.1046/j.1365-2362.33.s2.5.x
25. Lewin AJ, Arvay L, Liu D, Patel S, Woerle H-J (2010) Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Diabetologia 53(Suppl 1):S326. Poster 821, presented at the European association for the study of diabetes 46th annual meeting, Stockholm, Sweden, 20-24 Sept 2010
26. Owens DR, Swallow R, Jones P, Dugi KA, Woerle H-J (2010) Linagliptin improves glycemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain or hypoglycemia. Poster 548-P, presented at the 70th scientific sessions of the American diabetes association, Orlando, Florida, June 25-29, 2010. Abstract available at: http://professional. diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79496. Accessed 17 Nov 2010
27. SS Rathore JP Curtis Y Wang MR Bristow HM Krumholz 2003 Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 871 878 12588271 10.1001/jama.289.7.871 1:CAS:528:DC%2BD3sXht12ksL4%3D (Pubitemid 37430346)
28. S Retlich B Withopf A Greischel A Staab U Jaehde H Fuchs 2009 Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)-investigations in DPP-4 deficient and wildtype rats Biopharm Drug Dispos 30 422 436 19771584 10.1002/bdd.676 1:CAS:528:DC%2BD1MXhtlSlurvP
29. JI Schwartz NG Agrawal M Wehling BJ Musser CP Gumbs N Miechiels M De Smet JA Wagner 2008 Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib Br J Clin Pharmacol 66 811 817 18823299 10.1111/j.1365-2125.2008.03285.x 1:CAS:528:DC%2BD1MXhtVWksbs%3D
30. R Sechaud A Robeva R Belleli S Balez 2008 Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin Int J Clin Pharmacol Ther 46 519 526 18826866 1:CAS:528:DC%2BD1cXhsVaqt7zK
31. AA Tahrani MK Piya AH Barnett 2009 Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus Adv Ther 26 249 262 19330494 10.1007/s12325-009-0014-9 1:CAS:528:DC%2BD1MXksVClsLw%3D
32. M-R Taskinen J Rosenstock I Tamminen R Kubiak S Patel KA Dugi H-J Woerle 2011 Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled study Diabetes Obes Metab 13 65 74 21114605 10.1111/j.1463-1326.2010.01326.x 1:CAS:528:DC%2BC3MXlslamug%3D%3D